Chiara Zecca

Summary

Affiliation: Oncology Institute of Southern Switzerland
Country: Switzerland

Publications

  1. doi request reprint Hydrocephalus during natalizumab treatment
    Chiara Zecca
    Servizio Cantonale di Neurologia, Ospedale Civico, Via Tesserete 46, 6903, Lugano, Switzerland
    Neurol Sci 31:635-7. 2010
  2. doi request reprint Tolerability and acceptance of prolonged low/delayed mitoxantrone regimens in patients with worsening multiple sclerosis
    Chiara Zecca
    Neurocenter of Southern Switzerland, Ospedale Regionale, Via Tesserete 46, Lugano, Switzerland
    Eur Neurol 65:40-5. 2011
  3. pmc Interferon beta 1b following natalizumab discontinuation: one year, randomized, prospective, pilot trial
    Claudio Gobbi
    Neurocenter of Southern Switzerland, Ospedale Regionale di Lugano, Lugano, Switzerland
    BMC Neurol 13:101. 2013
  4. ncbi request reprint Chronic cerebrospinal venous insufficiency (CCSVI) and multiple sclerosis (MS): a critical review
    Chiara Zecca
    Servizio di Neurologia, Neurocentro della Svizzera Italiana, Ospedale Regionale di Lugano, Switzerland
    CNS Neurol Disord Drug Targets 10:757-61. 2011
  5. doi request reprint Diffusion-weighted imaging in acute demyelinating myelopathy
    Chiara Zecca
    Servizio di Neurologia e Neuroradiologia, Neurocenter of Southern Switzerland, Ospedale Regionale di Lugano, Via Tesserete 46, 6903, Lugano, Switzerland
    Neuroradiology 54:573-8. 2012

Collaborators

Detail Information

Publications5

  1. doi request reprint Hydrocephalus during natalizumab treatment
    Chiara Zecca
    Servizio Cantonale di Neurologia, Ospedale Civico, Via Tesserete 46, 6903, Lugano, Switzerland
    Neurol Sci 31:635-7. 2010
    ..Treating neurologists should be aware of this possible complication in selected subsets of patients...
  2. doi request reprint Tolerability and acceptance of prolonged low/delayed mitoxantrone regimens in patients with worsening multiple sclerosis
    Chiara Zecca
    Neurocenter of Southern Switzerland, Ospedale Regionale, Via Tesserete 46, Lugano, Switzerland
    Eur Neurol 65:40-5. 2011
    ....
  3. pmc Interferon beta 1b following natalizumab discontinuation: one year, randomized, prospective, pilot trial
    Claudio Gobbi
    Neurocenter of Southern Switzerland, Ospedale Regionale di Lugano, Lugano, Switzerland
    BMC Neurol 13:101. 2013
    ..The objective of this study is to compare disease activity in MS patients who continued on NTZ treatment to those who were switched to subcutaneous interferon 1b (IFNB) treatment...
  4. ncbi request reprint Chronic cerebrospinal venous insufficiency (CCSVI) and multiple sclerosis (MS): a critical review
    Chiara Zecca
    Servizio di Neurologia, Neurocentro della Svizzera Italiana, Ospedale Regionale di Lugano, Switzerland
    CNS Neurol Disord Drug Targets 10:757-61. 2011
    ..Until credible scientific evidence replicates the original results, any proposed invasive treatments of CCSVI should be discouraged...
  5. doi request reprint Diffusion-weighted imaging in acute demyelinating myelopathy
    Chiara Zecca
    Servizio di Neurologia e Neuroradiologia, Neurocenter of Southern Switzerland, Ospedale Regionale di Lugano, Via Tesserete 46, 6903, Lugano, Switzerland
    Neuroradiology 54:573-8. 2012
    ..Few publications have investigated the application of DWI for inflammatory demyelinating lesions. The purpose of the study was to describe diffusion-weighted imaging characteristics of acute, spinal demyelinating lesions...